Monopar Therapeutics Files 8-K on Shareholder Vote Matters

TL;DR

Monopar Therapeutics is holding a shareholder vote on June 17th. Details to follow.

AI Summary

Monopar Therapeutics Inc. filed an 8-K on June 23, 2025, reporting a submission of matters to a vote of security holders on June 17, 2025. The company, incorporated in Delaware, is involved in the pharmaceutical preparations industry and is headquartered in Wilmette, Illinois.

Why It Matters

This filing indicates that Monopar Therapeutics is seeking approval from its shareholders on specific corporate actions, which could impact the company's future direction and governance.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder vote, not indicating any immediate financial distress or significant operational change.

Key Numbers

• 001-39070 — SEC File Number (Identifies the company's filing history with the SEC.)
• 32-0463781 — I.R.S. Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Monopar Therapeutics Inc. (company) — Registrant
• June 17, 2025 (date) — Date of earliest event reported
• June 23, 2025 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• Wilmette, IL (location) — Principal executive offices

FAQ

From the Filing

0001437749-25-020959.txt : 20250623 0001437749-25-020959.hdr.sgml : 20250623 20250620180023 ACCESSION NUMBER: 0001437749-25-020959 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250617 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20250623 DATE AS OF CHANGE: 20250620 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 251062542 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 8-K 1 mnpr20250619_8k.htm FORM 8-K mnpr20250619_8k.htm false 0001645469 0001645469 2025-06-17 2025-06-17         UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): June 17, 2025   MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter)   Delaware   001-39070   32-0463781 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   1000 Skokie Blvd. , Suite 350 , Wilmette , IL   60091 (Address of principal executive offices)   (Zip Code)   ( 847 ) 388-0349 Registrant’s telephone number, including area code   N/A (Former name or former address, if changed since last report)   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock , $0.001 par value   MNPR   The Nasdaq Stock Market LLC (Nasdaq Capital Market)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company  ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐         1   Item 5.07    Submission of Matters to a Vote of Security Holders.   On June 17, 2025, Monopar Therapeutics Inc. (“Monopar” or the “Company”) held its Annual Meeting. A total of 6,115,214 shares of the Company’s common stock were entitled to vote as of April 25, 2025, the record date for the Annual Meeting, of which 5,048,394 shares were represented in person or by proxy at the Annual Meeting. At the Annual Meeting, the stockholders of the Company voted on the following proposals, each of which is described in greater detail in the Company’s definitive proxy stateme